Robert H. Eckel, M.D.
University of Colorado
Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine - Division of Endocrinology, Metabolism and Diabetes, and Cardiology
Professor of Physiology and Biophysics
Program Director, Adult General Clinical Research Center
Dr. Eckel received both his Bachelor of Sciences in Bacteriology (1969) and his Medical Doctorate (1973) from the University of Cincinnati. He did his Housestaff training in Internal Medicine at the University of Wisconsin Hospitals (1974-1976) and from there did a senior fellowship in Endocrinology and Metabolism at the University of Washington in Seattle. Dr. Eckel was then appointed as Assistant Professor of Medicine at the University of Colorado School of Medicine (1979) where he is now Professor of Medicine and holds the Charles A. Boettcher Endowed Chair in Atherosclerosis. In addition, Dr. Eckel has held joint appointments in the Department of Biochemistry, Biophysics and Genetics (1989-1995), the Department of Physiology and Biophysics, the Department of Food Science and Human Nutrition at Colorado State University, and an adjunct appointments in the Department of Clinical Pharmacy and in the Department of Integrative Physiology at the University of Colorado at Boulder. He is also the Director of the Lipid Clinic at University Hospital.
Presently Dr. Eckel’s research is focused on the relationship between nutrition, insulin action, energy balance and body weight regulation with experiments carried out in both humans and mice. Dr. Eckel's research has led to his involvement and presidency in a number of national organizations, including the American Heart Association, the Western Society for Clinical Investigation, the North American Association for the Study of Obesity, and the Association for Patient Oriented Research.
Aug 13, 2016
Cardiology, Exclusive Interviews
In part 3 of this exclusive interview, Dr. Eckel discusses the new PCSK9 Inhibitors and their LDL-lowering effects, and why they are beneficial for statin-intolerant patients.
Read More »
Aug 13, 2016
SGLT-2 Therapy Center
In part 2 of this exclusive interview, Dr. Eckel discusses the new diabetes drugs that offer treatment benefits beyond glucose control, and why 1 + 1 + 1 + 1 may add up to more than 4 when impacting multiple risks.
Read More »
Aug 13, 2016
Exclusive Interviews, Type 1 Diabetes, Type 2 Diabetes
In Part 1 of this exclusive interview, Dr. Eckel discusses the new PCSK9 inhibitors, treating complicated patients, and the challenges of type 2.
Read More »